B7-33 (6mg)

B7-33 (6mg) is a lyophilized research peptide synthesized, purified, and lyophilized in the USA. Each production batch is purified by repeated rounds of reverse-phase HPLC and identity-confirmed by mass spectrometry.

B7-33 (6mg) is often included in comparative panels alongside other short-chain repair peptides to map functional differences.

Laboratory work on B7-33 (6mg) emphasizes reproducible dosing and purity verification before experimental application.

Current literature on B7-33 (6mg) explores its stability profile and bioactivity under defined buffer and temperature conditions.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with B7-33 (6mg). Summaries are provided for orientation only and reflect the cited sources.

The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy^[1] — This experimental study compared the single-chain relaxin mimetic B7-33 with the ACE inhibitor perindopril in an experimental model of cardiomyopathy. The authors reported that B7-33 maintained the cardioprotective effects of native relaxin and more rapidly reduced left ventricular fibrosis. The findings support B7-33 as a potential therapeutic candidate in cardiac remodeling. (Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023)

Further Developments towards a Minimal Potent Derivative of Human Relaxin-2^[2] — This work described further structure-activity developments toward a minimal potent derivative of human relaxin-2. The authors refined the peptide design to identify shorter active analogs of the native hormone. The research is relevant to the development of simplified relaxin mimetics such as B7-33. (International journal of molecular sciences 2023)

Analgesic effect of central relaxin receptor activation on persistent inflammatory pain in mice: behavioral and neurochemical data^[3] — This study examined the analgesic effect of central activation of relaxin receptors on persistent inflammatory pain in mice. The authors provided behavioral and neurochemical evidence for pain-relieving actions of relaxin receptor signaling. The findings suggest that relaxin-related peptides may have applications beyond the cardiovascular system. (Pain reports 2021)

A Lipidated Single-B-Chain Derivative of Relaxin Exhibits Improved In Vitro Serum Stability without Altering Activity^[4] — This study investigated a lipidated single B-chain derivative of relaxin and reported improved in vitro serum stability without altering receptor activity. The authors evaluated how lipidation affects the pharmacological profile of the single-chain peptide. The findings inform the design of more stable relaxin-based peptides such as B7-33. (International journal of molecular sciences 2023)

References

1. Alam F, Gaspari TA, Kemp-Harper BK, Low E, Aw A, Ferens D, Spizzo I, Jefferis AM, Praveen P, Widdop RE, Bathgate RAD, Hossain MA, Samuel CS. "The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023. pubmed.ncbi.nlm.nih.gov/36753958/
2. Handley TNG, Praveen P, Tailhades J, Wu H, Bathgate RAD, Hossain MA. "Further Developments towards a Minimal Potent Derivative of Human Relaxin-2." International journal of molecular sciences. 2023. pubmed.ncbi.nlm.nih.gov/37628851/
3. Abboud C, Brochoire L, Drouet A, Hossain MA, Hleihel W, Gundlach AL, Landry M. "Analgesic effect of central relaxin receptor activation on persistent inflammatory pain in mice: behavioral and neurochemical data." Pain reports. 2021. pubmed.ncbi.nlm.nih.gov/34159282/
4. Praveen P, Wang C, Handley TNG, Wu H, Samuel CS, Bathgate RAD, Hossain MA. "A Lipidated Single-B-Chain Derivative of Relaxin Exhibits Improved In Vitro Serum Stability without Altering Activity." International journal of molecular sciences. 2023. pubmed.ncbi.nlm.nih.gov/37047588/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.